Clinical Report: Analysis of Sacubitril/Valsartan Prescribing Trends in Hypertension
Overview
This study analyzes the prescribing patterns of sacubitril/valsartan (S/V) among hypertensive patients in Japan, revealing that the majority are prescribed S/V in combination with calcium channel blockers. The study reports a discontinuation rate of S/V within 90 days of initiation.
Background
Sacubitril/valsartan (S/V) has been recently approved for the treatment of hypertension in Japan, expanding its use beyond heart failure. Understanding real-world prescribing patterns is crucial, as current guidelines provide limited recommendations on its use in combination with other antihypertensive agents. This study addresses the gap in evidence regarding S/V's application in hypertensive patients without heart failure.
Data Highlights
Parameter
Value
Total Patients
9,486
Median Age
79 years
Men
50.6%
S/V with CCB
63.6%
S/V Monotherapy
22.5%
S/V Triple Therapy
11.8%
Discontinuation Rate at 90 Days
11.8%
Key Findings
63.6% of patients received S/V in combination with a calcium channel blocker (CCB).
22.5% of patients were prescribed S/V as monotherapy.
11.8% of patients were on triple therapy with S/V, CCB, and thiazide diuretic.
55.5% continued S/V plus a CCB at day 90.
26.0% remained on S/V monotherapy at day 90.
Approximately half of those on triple therapy discontinued the thiazide diuretic within 30 days.
Clinical Implications
The findings indicate that S/V is frequently prescribed in combination with CCBs. The discontinuation rates are noted.
Conclusion
This study provides insights into the prescribing patterns of sacubitril/valsartan for hypertension in Japan, indicating a preference for combination therapy with CCBs and a noted discontinuation rate.
